&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2026-05-27, 08:18

Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III NSCLC
Basil Slack

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2026-03-13, 20:54

Junshi Biosciences Announces 2025 Full Year Financial Results and Provides Corporate Updates
Bonita Conti

Notified -

&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif; 2026-02-25, 07:30

Junshi Biosciences Announces Strategic Collaboration with Antengene to Evaluate Combination Therapy with JS207 (PD-1/VEGF BsAb) and ATG-037 (Oral CD73 Inhibitor)

Notified -

Popular Posts